반응식
[CH:1]1([CH2:4][O:5][C:6]2[N:11]=[C:10]([C:12]([OH:14])=O)[CH:9]=[CH:8][C:7]=2[N:15]2[CH2:18][C:17]([F:20])([F:19])[CH2:16]2)[CH2:3][CH2:2]1.[CH:21]1([C:24]([CH3:32])([C:26]2[N:30]=[C:29]([CH3:31])[O:28][N:27]=2)[NH2:25])[CH2:23][CH2:22]1>>[CH:21]1([C:24]([NH:25][C:12]([C:10]2[CH:9]=[CH:8][C:7]([N:15]3[CH2:18][C:17]([F:20])([F:19])[CH2:16]3)=[C:6]([O:5][CH2:4][CH:1]3[CH2:2][CH2:3]3)[N:11]=2)=[O:14])([C:26]2[N:30]=[C:29]([CH3:31])[O:28][N:27]=2)[CH3:32])[CH2:23][CH2:22]1참가 물질
3
반응물 2
생성물 1
실험 절차
The title compound was synthesized in analogy to Example 1, using 6-cyclopropylmethoxy-5-(3,3-difluoro-azetidin-1-yl)-pyridine-2-carboxylic acid (Example 69 b) and α-cyclopropyl-α,5-dimethyl-1,2,4-oxadiazole-3-methanamine (CAN 1155536-64-3) as starting materials. MS (EI): m/e=434.5 [M+H]+.
출처 및 근거
- ORD 기록
- ord-dd3657c7a2d44475a95cff24af220429
- 출처 데이터셋
- uspto-grants-2016_04
- 특허 번호
- US09321727B2
연결된 노트
불러오는 중…